Alicia Algeciras-Schimnich, Ph.D., discusses how Mayo Clinic Laboratories’ new noninvasive blood test for Alzheimer’s disease identifies the p-tau217 biomarker, which is associated with the accumulation of amyloid beta in the brain. Positive test results can facilitate access to disease-modifying therapies.
(
00:32):
Dr. Algeciras, could you just provide a little bit of background on your role at Mayo Clinic?
So before we get into the test itself, can you just explain a little bit about the disease state and especially some of the recent changes?
(
07:39)
So can you explain a little bit more about what the results that our clients will receive look like?
(
10:30)
Can you just give a quick overview of how our test is unique compared to those on the market?
(
12:24)
What patients should have this testing performed, Dr. Algeciras and if you have any tips on which patients should not, please include that as well?
(
14:42)
Let's talk now about how those results are used in patient care.
(
16:31)
One more question, just summarize for our listeners what you're most excited about with this new test.